Therapeutics Emerging Therapies
RRM Academy Synopsis
Light therapy and a pill had similar dysmenorrhea response rates
In a randomized trial of 156 women aged 16 to 35 with primary dysmenorrhea, low-level light therapy on two acupoints reached the main pain target at a rate similar to a combined pill: 73.6% versus 85.7% among the women who completed the trial. The pill produced the larger mean drop in pain score.
Key Findings
- The share of women with a 33% or greater drop in pain score was 73.6% with light therapy and 85.7% with the combined pill (p = 0.084).
- Mean pain scores fell 39.3 ± 2.6% with light therapy and 59.5 ± 4.2% with the combined pill (p < 0.001).
- Prostaglandin E2 fell significantly from baseline in both groups and did not differ between them (p = 0.51). Serum nitric oxide levels held steady in both.
- Painkiller requests fell from 9 women (light) and 2 (pill) at week 4 to 4 and 1 at week 8, and none at the end.
- Twelve women reported adverse effects. Three in the light group had a transient skin rash, and nine in the pill group had decreased appetite. All were minor, with no serious adverse effect.
Interpretation
This 12-week randomized trial ran at eight hospitals in seven provinces. Participants knew their assigned treatment. Of 156 women randomized, 135 completed it. Ultrasound and examination showed a normal pelvis, and endometriosis or adenomyosis excluded entry. The authors note that psychological effects could not be ruled out, since pain was rated on subjective scales and blinding was impossible. The comparator was one combined pill formulation. In women with a normal pelvis on screening, the light device reached the main pain target at a rate not statistically different from the pill (p = 0.084). The pill produced the larger drop in mean pain score (p < 0.001).
RRM Context
The authors call combined pills, a suppressive medication, a mainstay for primary dysmenorrhea. Restorative reproductive medicine looks for the cause of cycle pain. This trial enrolled only women with a normal pelvis on ultrasound and examination. Light therapy eases pain without suppressing the cycle.
Abstract
We aimed to compare low-level light therapy with oral contraceptive pills for pain relief and serum levels of nitric oxide and prostaglandin E2 in patients with primary dysmenorrhoea. This was a randomised, active comparator-controlled, multicentre study. In total, 156 patients were randomised to receive either low-level light therapy with light-emitting diodes (LED) applying on two acupoints, namely, conception vessel 4 (CV4) and CV6 or conventional treatment with oral Marvelon, 30 µg of ethinyl estradiol and 150 µg of desogestrel (DSG/EE), for three consecutive menstrual cycles. The main outcome was the proportion of patients who achieved 33% or more decrease in pain scores measured using the visual analogue scale, which was deemed as efficient rate. Absolute changes in visual analogue scale scores, serum levels of nitric oxide (assessed by nitrites and nitrates reflecting nitric oxide metabolism) and prostaglandin E2 (measured by enzyme-linked immunosorbent assay) were the secondary outcomes. A total of 135 patients completed the study (73 in the light therapy group and 62 in the DSG/EE group). The efficient rate at the end of treatment was comparable between the groups (73.6% vs. 85.7%, χ2 = 2.994, p = 0.084). A more significant reduction in pain scores was observed in the DSG/EE group (39.25% vs. 59.52%, p < 0.001). Serum levels of prostaglandin E2 significantly decreased from baseline but did not differ between groups (- 109.57 ± 3.99 pg/mL vs. - 118.11 ± 12.93 pg/mL, p = 0.51). Nitric oxide concentration remained stable in both groups. Low-level light therapy with LED-based device applied on acupuncture points CV4 and CV6 demonstrated a similar level of dysmenorrhoea pain reduction to DSG/EE combined contraceptive. Both treatment modalities achieved clinically meaningful levels of pain reduction. Registration on ClinicalTrials.gov: TRN: NCT03953716, Date: April 04, 2019.


